Additionally, the mIF on TMA distinguished Metab-HCC and EMT-HCC based on the expression of ARG1 and S100A6, which also confirmed the shorter OS (median: 48.7 months vs. not reached, P < 0.001, Fig. 4K) and RFS (median: 33.1 vs. 70.1 months, P < 0.001, Fig. 4L) of EMT-HCC. Here, S100A6 is linked to hepatocellular carcinoma.